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Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent
stroke and other cardiovascular diseases and commonly suffer from reduced quality of life. We aimed to
determine whether the disease management programme STROKE-CARD can prevent cardiovascular diseases
and improve quality of life in these patients.
Methods: In this pragmatic open-label two-centre randomised controlled trial with blinded outcome assess-
ment, we randomly assigned patients with acute ischaemic stroke or TIA (ABCD2 score 3) in a 2:1 ratio to
receive STROKE-CARD care or standard care. STROKE-CARD care is a disease management programme by a
multidisciplinary stroke team that comprises a standardised 3-month visit and access to a web-based patient
portal targeting risk factor management, post-stroke complications, comorbidities and cardiovascular warn-
ing signs, rehabilitation demands, and patient education, counselling, and self-empowerment. Co-primary
outcomes were analysed on an intention-to-treat basis and were: (i) major cardiovascular disease events
defined as nonfatal ischaemic or haemorrhagic stroke, nonfatal myocardial infarction, or vascular death
occurring between hospital discharge and 12 months; and (ii) health-related quality of life at 12 months
quantified with the EuroQol-5-Dimensions-3-Levels (EQ-5D-3L) overall utility score. This trial is registered
with ClinicalTrials.gov, number NCT02156778.
Findings: Of 2149 patients enrolled between January 2014 and December 2017 (mean age 69 years, 41%
female, 83% with ischaemic stroke, 17% with TIA), 1438 were assigned to STROKE-CARD care and 711 to stan-
dard care. Major cardiovascular disease events occurred in 78 patients in the STROKE-CARD care group (5.4%)
and in 59 patients in the standard care group (8.3%) (hazard ratio, 0.63; 95% confidence interval: 0.45-0.88;
P=0.007). STROKE-CARD care also led to a better EQ-5D-3L overall utility score at 12 months (P<0.001).
Among pre-specified secondary outcomes, STROKE-CARD care improved all individual EQ-5D-3L dimensions
and functional outcome on the modified Rankin Scale at 12 months. Post hoc explanatory analyses identified
considerable demands for additional rehabilitation and refinement of preventive therapy regimes at the 3-
month visit and high proportions of post-stroke complications and warning signs of imminent cardiovascular
diseases within the first three months.
Interpretation: The pragmatic and easily implementable STROKE-CARD care programme reduced cardiovas-
cular risk and improved health-related quality of life and functional outcome in patients with acute ischae-
mic stroke or TIA.Keywords:
Randomised controlled trial
Ischaemic stroke
Transient ischaemic attack
Disease management programme
Secondary prevention
Quality of lifeMedical University of Innsbruck, Anichstraße 35, Innsbruck, Austria.
), stefan.kiechl@i-med.ac.at (S. Kiechl).
Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Stroke is the second leading cause of death worldwide and one of
the main contributors to disability. According to the latest Global Bur-
den of Disease Study, there are 80.1 million individuals that have had
a stroke and stroke is responsible for 6.2 million deaths each year
worldwide [1,2]. Patients with ischaemic stroke and those with tran-
sient ischaemic attack (TIA) are at elevated risk of subsequent stroke,
particularly in the first year after the event (one-year cumulative risk
5.1%-13.1%) [3,4]. Importantly, recurrent strokes are associated with
higher social and economic impact, higher case fatality, and worse
clinical outcome than first-ever strokes [5]. Risk for other atheroscle-
rotic cardiovascular diseases (CVD) is also increased after stroke or
TIA [6]. It has been estimated that guideline-compliant treatment
may prevent about 80% of recurrent CVD events [7], but  in reality
 recommended target levels for modifiable risk factors are rarelyachieved [8]. Moreover, post-stroke complications frequently mani-
fest after hospital discharge and may remain undetected. The burden
of post-stroke complications, residual deficits, and inadequate medi-
cal and psycho-social care contribute to long-term disability and
reduced quality of life in these patients.
For these reasons, comprehensive disease management pro-
grammes performed by a multidisciplinary stroke team are required
that focus on patient care after hospital discharge. Prior trials showed
beneficial effects on blood pressure control but did not yield convinc-
ing evidence for improvements of other modifiable risk factors nor
reductions in recurrent CVD events [9]. Furthermore, effects on qual-
ity of life and long-term functional independence are particularly
under-investigated [9].
We herein report the results of a large randomised controlled trial
employing the multifaceted disease management programme
STROKE-CARD care to patients with ischaemic stroke or TIA. Our trial
had two co-primary endpoints. It aimed to (i) reduce one-year risk of
major cardiovascular events and (ii) improve health-related quality
of life one year after the index event.
2. Methods
2.1. Trial design
We conducted this pragmatic block-randomised controlled open-
label trial with blinded outcome assessment at Innsbruck University
Hospital and Hospital St. John’s of God Vienna. Its design has been
described previously [10]. The study was approved by the ethics
committees of the two study centres and is registered with Clinical-
Trials.gov, number NCT02156778. Enrolled patients provided written
informed consent.
2.2. Patients
Patients aged 18 years hospitalised due to acute ischaemic
stroke (defined according to American Heart Association criteria
[11]) or TIA (ABCD2 score 3 or higher [12]) were eligible for inclusion.
Eligible patients were enrolled in the trial during the acute hospital
stay. Exclusion criteria were malignancies or other severe diseases
with an estimated life expectancy <1 year, drug addiction, severe
alcohol abuse, residence outside the catchment area, or severe dis-
ability with low probability of successful rehabilitation indicated by a
modified Rankin Scale (mRS) score of 5 at hospital discharge.
2.3. Interventions
Patients were allocated to STROKE-CARD or standard care in a 2:1
ratio by block-randomisation using prescheduled alternating blocks
of 8 and 4 weeks. Allocation was based on the exact date and time of
the qualifying event [10]. Standard care involved in-hospital patient
counselling and education, dietary advice, smoking cessation sup-
port, printed information materials (book: “After a stroke”), and a
detailed discharge-from-hospital report (including patient-tailored
target levels for risk factor management) to the general practitioner
and the patient. Patients with persisting deficits were transferred to
rehabilitation services within the scope of the local stroke pathways
[13]. Selected high-risk patients (e.g. patients after carotid surgery)
were seen in the outpatient clinics. As part of the Austrian Stroke
Unit Registry (outside the current study), study nurses conducted
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tional outcome [14].
In addition to standard care, STROKE-CARD care involved an
outpatient appointment for patients and care-givers scheduled
three months after the index event and lasting two to three hours
[10]. This additional appointment was performed by a multidisci-
plinary team of stroke physicians, nurses, physiotherapists, and
occupational and speech therapists. It had the following aims: (i)
to re-evaluate stroke/TIA aetiology (with potential changes in
prevention strategies), (ii) to reassess risk factor levels and opti-
mise secondary prevention (adapting medication lists and rein-
forcing drug adherence), (iii) to systematically screen for post-
stroke complications and other health problems (holistic
approach with initiation of therapy and/or referral to specialists),
(iv) to assess rehabilitation demands (with referral to rehabilita-
tion services), (v) to manage new-onset CVD and warning signs
of imminent CVD (including referral to revascularisation proce-
dures if appropriate), and (vi) to enhance patient self-empower-
ment and knowledge about CVD and to counsel patients on all
matters raised by themselves or their care-givers (Supplementary
Methods). The median time from index event to the 3-month
outpatient appointment in the STROKE-CARD care group was
99 days (interquartile range [IQR] 93-107) (in-person attendance
rate 83.3%). Patients and care-givers were also given access to the
web-based patient portal “MyStrokecard” for risk factor monitor-
ing, ascertainment of post-stroke complications, and extended
patient education and were offered to contact the study person-
nel in case of health problems. They received training for this e-
tool during hospital stay with a tailored composition according to
individual risk profiles and target levels and introduction to easily
applicable screening tools for post-stroke complications.
2.4. Outcomes
All trial endpoints were pre-specified. The composite CVD end-
point was adjudicated by a committee blinded to group assignment
using standard diagnostic criteria [11,15]. Details on outcome defini-
tions and adjudication procedures are provided in the Supplementary
Methods. Co-primary outcomes were (i) a composite outcome of
major cardiovascular events defined as nonfatal ischaemic stroke,
nonfatal haemorrhagic stroke, nonfatal myocardial infarction, or vas-
cular death (i.e. sudden cardiac death or death due to acute myocar-
dial infarction, ischaemic or haemorrhagic stroke, heart failure,
cardiovascular procedures, pulmonary embolism, or peripheral artery
disease) between hospital discharge and the 12-month visit; and (ii)
health-related quality of life at the 12-month visit, self-reported by
the patient with a questionnaire and quantified with the EuroQol-5-
Dimensions-3-Levels (EQ-5D-3L) overall health utility score [16]
with rescaled European visual analogue scale weights [17]. Defini-
tions of pre-specified secondary outcomes and potential side effects
of intensified secondary prevention are provided in the Supplemen-
tary Methods.
2.5. Statistical analysis
Analyses were conducted according to a pre-specified statistical
analysis plan (Supplementary File 3). We initially planned to enrol
2400 patients to detect a reduction in 12-month CVD risk from 15%
with standard care to 10% with STROKE-CARD care with 90% power
(a=0.05). When observing a lower-than-expected attrition rate
(including withdrawals of consent and losses to follow-up) between
January 2014 and June 2017, the target sample size was revised to
2160 patients. For the EQ-5D-3L overall health utility score, we esti-
mated that this sample size allowed detecting a difference of 0.03
with 90% power, assuming a standard deviation (SD) of 0.2. No
interim analyses were performed.The principal analysis was conducted as a complete case analysis
and on an intention to treat basis. We considered the trial successful
only if the analyses of both co-primary endpoints yielded two-sided
P values  0.05 [18]. For the descriptive analysis and analysis of sec-
ondary outcomes and subgroups, we used the Hochberg procedure
to correct for multiple testing [18]. We analysed time-to-event data
from hospital discharge to occurrence of the event of interest, death,
or end of follow-up, whichever had occurred first. For patients who
had attended the 12-month visit late (i.e. >13 months after hospital
discharge), time-to-event data were censored at 13 months. Cox
regression models were stratified by trial centre to account for poten-
tial clustering and differences in the baseline hazard function. The
proportional hazards assumption was checked using Schoenfeld
residuals and was met (Supplementary Figure 1). As we did not antic-
ipate overdispersion, we pre-specified to analyse dichotomous out-
comes using Poisson regression with robust error variance and
adjustment for trial centre [19]. Ordinal logistic regression was used
to test whether the distribution of mRS categories differed between
trial arms; the proportional odds assumption was tested with the
Brant test and was met. Due to a markedly skewed distribution, the
Mann Whitney U-test (rather than linear regression as initially pro-
posed in the design paper [10]) was used to test for a difference
between trial arms in the 12-month EQ-5D-3L overall health utility
score. Finally, we performed pre-specified sensitivity analyses for the
CVD outcome (i) adjusting for age, sex, and type of index event, (ii)
analysing patients as treated, (iii) analysing only patients that were
treated per protocol, and (iv) excluding patients whose index event
had been a TIA with an ABCD2 score of 3. We also performed pre-
specified subgroup analyses according to sex, age (<70 vs. 70
years), type of index event, trial centre, and use of e-tool “MyStroke-
card”.
2.6. Role of the funding source
The funders had no role in study design, data collection, data anal-
ysis, or writing of the report. PW and SKi had full access to all data in
the study and had final responsibility for the decision to submit for
publication.
3. Results
3.1. Patients
Trial enrolment began on 3 January 2014 and was completed on
31 December 2017; the last follow-up visit was on 15 January 2019.
Of 3908 patients screened, 2399 were eligible for inclusion in the
trial, of which 2149 patients participated (89.6%) (Figure 1). A total of
1438 patients were allocated STROKE-CARD care and 711 standard
care. Follow-up for the composite CVD endpoint was complete. At
the 12-month visit, the EQ-5D-3L overall health utility score was
available for 2101 patients (97.8%) and the mRS score was available
for 2117 patients (98.5%).
Mean age was 69 years (SD 14); 41% were women. As index
event, 1791 patients (83%) had suffered an acute ischaemic stroke
and 358 a TIA (17%). Patients with ischaemic stroke had a median
National Institutes of Health stroke scale (NIHSS) score of 3 at
hospital admission (IQR 1-6) and 14% had suffered a stroke prior
to the index event. Patients with a TIA had a median ABCD2 score
of 4 (IQR 3-5). Median duration of hospital stay was 9 days (IQR
6-13). Patients in both trial arms received the same medical
attention as indicated by similar proportions of thrombolysis and
thrombectomy, access to post-discharge rehabilitation, intake of
preventive medication at discharge, and length of hospital stay
(Table 1). Baseline characteristics were balanced between the trial
arms (Table 1), but a few differed between patients enrolled at
the two study centres (Supplementary Table 1).
Fig. 1. CONSORT diagram. mRS denotes modified Rankin Scale. For the per-protocol and as treated analysis, patients were classified as having received STROKE-CARD care if they
had attended the 3-month visits in person and/or had used the web-based patient portal during follow-up.
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Over a median follow-up duration of 12.1 months (IQR 11.6-12.4),
137 major cardiovascular events occurred, including 95 nonfatal
strokes (88 ischaemic, 7 haemorrhagic), 18 nonfatal myocardial
infarctions, and 24 vascular deaths. 78 events occurred in patients
allocated STROKE-CARD care (5.4%) and 59 in patients allocated stan-
dard care (8.3%) (Fig. 2A), corresponding to incidence rates per 1000
person-years of 57 (95% confidence interval [CI]: 45-71) and 89 (69-
115). Compared with standard care, the hazard ratio (HR) for CVD
with STROKE-CARD care was 0.63 (95% CI: 0.45-0.88; P =0.007). The
number needed to treat to prevent one major CVD event in the first
year after the stroke or TIA was 35 (95% CI: 19-154).
STROKE-CARD care also resulted in a better health-related quality
of life after 12 months. The median EQ-5D-3L health utility score was0.783 (IQR 0.687-1.000) in the STROKE-CARD care group and 0.779
(IQR 0.573-1.000) in the standard care group (P < 0.001). A score of
1.0 indicating absence of problems in all five EQ-5D-3L dimensions
was achieved by 43% in the STROKE-CARD care group and 32% in the
standard care group (relative risk 1.36; 95% CI: 1.20-1.54; P < 0.001)
(Fig. 2B). A violin plot of the EQ-5D-3L overall health utility score at
12 months in the two groups is provided in Supplementary Figure 2.
3.3. Pre-specified secondary outcomes
When comparing STROKE-CARD with standard care, the HR was
0.96 (95% CI: 0.67-1.37; P=0.822; 6.3 vs. 6.5% cumulative risk) for the
composite outcome of stroke or TIA and 0.72 (0.47-1.10; P=0.131;
3.6 vs. 4.9% cumulative risk) for all-cause mortality (Fig. 3A and Sup-
plementary Fig. 3).
Table 1
Characteristics of patients enrolled in the trial.
Characteristics STROKE-CARD care Standard care
No. of patients Mean § SD, %, or median (IQR) No. of patients Mean § SD, %, or median (IQR)
Age (years) 1438 69 § 14 711 70 § 13
Female sex 1438 41% 711 41%
Index event
Ischaemic stroke 1438 82% 711 86%
Recurrent stroke 1180 14% 611 15%
NIHSS score at hospital admission 1180 3 (1-6) 611 3 (1-6)
Intravenous thrombolysis 1180 23% 611 21%
Mechanical thrombectomy 1180 5% 611 5%
Discharge to rehabilitation centre 1180 26% 611 27%
TIA 1438 18% 711 14%
ABCD2 score 258 4 (3-5) 100 4 (4-5)
TOAST classification
Large-artery atherosclerosis 1438 22% 711 17%
Cardiac embolism 1438 26% 711 27%
Small-artery occlusion 1438 20% 711 23%
Uncommon causes 1438 4% 711 5%
Undetermined causes 1438 28% 711 29%
Duration of hospital stay (days) 1438 9 (6-13) 711 9 (6-13)
Prior to index event
Modified Rankin Scale 1431 0 (0-0) 698 0 (0-0)
Physical activity (min/week) 749 373 (228-644) 346 340 (228-644)
Smoking status
Current smoker 1438 24% 711 23%
Ex-smoker 1438 34% 711 32%
Never smoker 1438 42% 711 45%
At hospital discharge
Comorbidities
Coronary heart disease 1438 16% 711 14%
Peripheral vascular disease 1438 8% 711 9%
Revascularisation procedures 1438 18% 711 18%
Hypertension 1438 80% 711 82%
Diabetes mellitus 1438 21% 711 20%
HbA1c (%) in patients with diabetes mellitus 295 7.3 § 1.6 142 7.4 § 1.6
Atrial fibrillation 1438 24% 711 26%
Intake of medication
Lipid-lowering medication 1438 81% 711 81%
Oral anticoagulants or antiplatelet therapy 1438 96% 711 94%
Oral anticoagulants in patients with AF 343 74% 188 71%
Systolic blood pressure (mmHg) 1407 134 § 18 700 136 § 18
Diastolic blood pressure (mmHg) 1407 77 § 12 700 78 § 12
LDL cholesterol (mmol/L) 1398 3.0 § 1.0 705 3.0 § 1.0
Body mass index (kg/m2) 1421 27 § 5 702 26 § 4
Estimated GFR (mL/min/1.73m2) 1438 71 § 20 711 71 § 20
Modified Rankin Scale 1438 1 (0-2) 711 2 (0-2)
Numbers are means and standard deviations, percentages or medians (IQR). Percentages may not total 100 because of rounding. There were no nominally sig-
nificant differences between the two groups in baseline characteristics when correcting for multiple testing. To convert values for LDL cholesterol to mg/dL,
multiply by 38.61. AF denotes atrial fibrillation, GFR glomerular filtration rate, HbA1c glycated haemoglobin, IQR interquartile range, LDL low-density lipopro-
tein, NIHSS National Institutes of Health Stroke Scale, SD standard deviation, and TIA transient ischaemic attack.
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issues with walking about, self-care, performing usual activities,
pain or discomfort, and anxiety or depression (Fig. 3B). Propor-
tions of patients achieving target risk factor levels at 12 months
did not differ significantly between trial arms (Fig. 3B). In the
control group, the quality of risk factor control was not assessed
prior to the 12-month visit.
Functional independence 12 months after the index
event (mRS 2) was achieved by 81.4% in the STROKE-CARD
care group and 76.1% in the standard care group (relative risk,
1.07; 95% CI: 1.02-1.12; P = 0.006). The common odds ratio for a
lower mRS score with STROKE-CARD care was 1.31 (95% CI:
1.12-1.55; P = 0.001) (Fig. 4) and remained significant when
adjusting for age, sex, and mRS at discharge (1.19; 95% CI: 1.00-
1.40; P = 0.044) and when excluding the 137 patients that expe-
rienced a major CVD event during follow-up (1.22; 95% CI: 1.03-
1.44; P = 0.024). Finally, risk of potential side effects of intensi-
fied secondary prevention did not differ between trial arms
(Fig. 5).3.4. Pre-specified sensitivity analyses
We observed effects of STROKE-CARD care on the CVD outcome simi-
lar to the principal analysis when: (i) adjusting for age, sex, and type of
index event (HR, 0.65; 95% CI: 0.46-0.91; P = 0.013); (ii) analysing
patients as treated (HR, 0.64; 95% CI: 0.46-0.90 P = 0.010); (iii) analysing
only patients that were treated per protocol (HR, 0.61; 95% CI: 0.43-0.87;
P = 0.006); (iv) excluding patients whose index event had been a TIA
with an ABCD2 score of 3; or (v) focusing the analysis on patient sub-
groups (Supplementary Figure 4). Sensitivity analyses for health-related
quality of life after 12months are provided in Supplementary Table 2.3.5. Post-hoc explanatory analyses
Reflecting on the positive results, we got granular with the spe-
cific interventions delivered in the STROKE-CARD care group at the
3-month visit and provide numbers of patients targeted by these
interventions in Supplementary Table 3. This analysis unravelled
Fig. 2. Effect of STROKE-CARD care on the co-primary outcomes. Panel A shows the
cumulative incidence of the composite cardiovascular disease endpoint; the inset
shows the same data on an enlarged y axis. Panel B shows the distribution across cate-
gories of the EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) health utility score at the 12-
month visit. Higher EQ-5D-3L values indicate better health-related quality of life. HR
denotes hazard ratio.
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post-stroke complications, considerable demands for additional rehabil-
itation, and frequent warning signs of imminent CVD (4.6% of patients)
within the first three months. Seven patients with new indications for
carotid revascularisation were identified at the 3-month visit.
In exploratory analyses, the HR for CVD was 0.75 (95% CI: 0.50-
1.12; P = 0.161) in patients with a mRS score of 0-2 at hospital dis-
charge and 0.39 (0.21-0.75; P = 0.005) in patients with a mRS score of
3-4 (P for interaction=0.096). HRs for individual components of the
composite CVD outcome were 0.81 (95% CI: 0.54-1.21; P = 0.297;
4.3 vs. 5.2% cumulative risk) for stroke, 0.32 (0.13-0.80; P = 0.014;
0.6 vs. 1.7% cumulative risk) for myocardial infarction, and 0.32
(0.16-0.66; P = 0.002; 0.9 vs. 2.7% cumulative risk) for vascular death.
These findings should be interpreted with caution because the study
was powered for the combined CVD endpoint.4. Discussion
Management of stroke and TIA has improved tremendously over
the past years with substantial advances in acute therapy,implementation of comprehensive pathways for stroke and TIA, and
approval of novel effective preventive treatments. As a main unmet
challenge, strategies of post-stroke care to maintain improved short-
term patient outcome in the long run have to be developed and
tested rigorously.
In our large-scale randomised controlled disease management
trial among patients with ischaemic stroke or TIA, STROKE-CARD
care reduced one-year cumulative incidence of CVD by about one
third from 8.3% to 5.4% and ameliorated the patients’ health-related
quality of life at 12 months (Fig. 2). Findings were consistent in pre-
specified subgroups and confirmed in the per-protocol analysis (Sup-
plementary Figure 4). Effect sizes tended to be higher in patients
with non-minor stroke compared to TIA and minor stroke (P for
interaction=0.096). Among secondary outcomes assessed at 12
months, we observed improvements in all individual dimensions of
the EQ-5D-3L overall health-utility score and in one-year functional
outcome, that each met the multiplicity-adjusted threshold for statis-
tical significance (Fig. 3).
Only few previous trials of disease management programmes in
stroke and TIA patients have focused on recurrent CVD. The SMART
trial randomising 47 hospitals in China to a structured care pro-
gramme or to usual care observed no effect on CVD outcomes after
12 months [20]. Limitations of this trial include a low uptake of the
intervention, imbalance in baseline characteristics across trial arms,
and its exclusive focus on risk factor control. In the DMP Stroke trial,
rates for incident vascular events were lower in the intensified care
group but statistical significance was not reached (HR 0.52; 95% CI:
0.24-1.17; P = 0.11) [21]. The recent large-scale INSPiRE-TMS trial
randomised patients with acute minor stroke or TIA to an intensified
secondary prevention programme or to conventional care and
reported improved achievements of secondary prevention targets
but no significant reduction in major vascular events [22]. Three dis-
ease management trials have addressed quality of life. Two reported
null effects [23,24], whereas the TaCAS study observed pronounced
effects of one or two simple post-discharge person-centred, self-
management interventions on quality of life [25].
Importantly, the STROKE-CARD care programme entailed changes
in the organisation of care, which can be achieved more easily than
sustained changes in patient behaviour  the prime focus of most
previous trials. STROKE-CARD care comprised a multifaceted 3-
month intervention by the multidisciplinary stroke team. Individual
measures in addition to counselling of patients and their care-givers
are summarised in Supplementary Table 3 and included: (i) refine-
ment of cardiovascular prevention strategies in order to achieve tar-
get levels or based on a reclassification of stroke aetiology [26,27] in
no less than 43% of patients; (ii) systematic identification and treat-
ment of post-stroke complications (exemplified in Supplementary
Table 3, 19.9%-49.4%); (iii) standardised assessment of residual defi-
cits and referral to additional rehabilitation in about one fifth of
patients; and (iv) detection and management of warning signs of
imminent CVD in 4.6% of patients.
These measures and respective achievements provide reasonable
explanations for the improved health-related quality of life and func-
tional outcome observed in our trial and provide also some clues for
understanding the CVD benefit. First, the number of patients report-
ing CVD warning signs within the first three months after the index
event was considerable and all were subjected to urgent pharmaco-
logical, endovascular, and surgical interventions. This procedure has
likely prevented CVD events. STROKE-CARD care patients probably
faced a reduced barrier to contact the hospital because the multidisci-
plinary stroke team formally extended its responsibility for them and
offered a contact phone number. Second, there is good reason to
assume that risk factor control was achieved earlier in the STROKE-
CARD care group given the extra counselling during the web-portal
introduction, the patients’ ambition to perform well at the 3-month
visit, and the multiple refinements of CVD prevention performed as
Fig. 3. Effect of STROKE-CARD care on the pre-specified secondary outcomes. Panel A shows outcomes STROKE-CARD aimed to prevent; Panel B shows outcomes STROKE-CARD
aimed to promote. *Indicates P values that met the pre-specified multiplicity-adjusted threshold for statistical significance. A single patient may have had multiple events and there-
fore may contribute information to more than one endpoint. AF denotes atrial fibrillation, CI confidence interval, EQ-5D-3L EuroQol 5-Dimensions 3-Levels, HbA1c glycated haemo-
globin, LDL low-density lipoprotein, and TIA transient ischaemic attack.
P. Willeit et al. / EClinicalMedicine 25 (2020) 100476 7part of the 3-month visit. At the end of the follow-up, risk factor con-
trol was similar in both trial arms (Fig. 3B) and overall better than in
previous real-world surveys in Europe [28], especially regarding the
proportion of patients with atrial fibrillation taking anticoagulants
(94.3%). Similar has been observed in the INSPiRE-TMS trial [22] and
attributed to the facts that patients in both trial arms were managed
by the same family doctors and trial inclusion per se enhances patient
awareness. It is important to recognise that the inadvertent benefit in
the control groups of INSPiRE-TMS and our trial may well have led to
an underestimation of true effect sizes.
Our trial has several unique features and strengths. We report on
a broad range of outcomes relevant in clinical practice, including
major CVD events, health-related quality of life, and one-year func-
tional outcome. Moreover, our study included patients with a broadspectrum of disease severities ranging from moderate-risk TIA to
major ischaemic stroke and recruited near 90% of all eligible patients.
Only patients unlikely to benefit from intensified secondary preven-
tion were excluded, such as patients with assumed life expectancy of
less than one year or permanent severe disability. Finally, full access
to clinical records from the relevant hospitals and family doctors
allowed complete and high-quality ascertainment of major cardio-
vascular outcomes, thereby reducing the potential for surveillance
bias. One limitation of our trial is that it was conducted in a highly
developed medical care system with advanced pathways for stroke
care [13]. Although findings are not easily extrapolated to less devel-
oped systems of stroke care, the potential benefit of the intervention
is presumably even higher. Moreover, block-randomisation is inferior
to a standard randomisation procedure. However, the potential of
Fig. 4. Functional outcome at 12 months assessed with the modified Rankin Scale. The graph shows the distribution of scores for disability on the modified Rankin Scale (which
range from 0 to 6, with higher scores indicating more severe disability) among patients in the standard care group versus patients in the STROKE-CARD care group. The numbers in
the bar are percentages of patients who had each score; the percentages may not sum to 100% because of rounding. When analysing the shift of patients across all modified Rankin
Scale categories at 12 months, the common odds ratio for a lower modified Rankin Scale score with STROKE-CARD care compared with standard care was 1.31 (95% confidence
interval: 1.12-1.55; P = 0.001). mRS denotes modified Rankin Scale.
8 P. Willeit et al. / EClinicalMedicine 25 (2020) 100476selection bias is limited by the facts that the exact time and date of
the stroke or TIA decided about patient allocation to the trial arms
and about 90% of eligible patients consented to participate through-
out the enrolment period. Importantly, patients in both trial arms
received the same medical attention as indicated by similar propor-
tions of thrombolysis and thrombectomy, access to post-discharge
rehabilitation, intake of preventive medication at discharge, and
length of hospital stay. Furthermore, uptake of the e-tool “MyStroke-
card” was limited in this primarily elderly study population (regular
use, 11.8%). While trial participants and study personnel were aware
of the assigned treatment (open-label), clinical outcomes wereFig. 5. Effect of STROKE-CARD care on potential side effects of intensified secondary preventi
A single patient may have had multiple events and therefore may contribute information to m
the type of outcome). The analysis of laboratory parameters (ALT, CK, and eGFR) involved onl
fidence interval, CK creatine kinase, and eGFR estimated glomerular filtration rate.adjudicated by a blinded endpoint committee using standardised
diagnostic criteria. Finally, our study was limited to a 12-month fol-
low-up. Thus, the sustainability of benefits over longer term remains
to be determined.
In conclusion, STROKE-CARD care reduced CVD risk and improved
health-related quality of life and functional outcome in patients with
acute ischaemic stroke or TIA. Given the pragmatic intervention,
STROKE-CARD care can easily be transferred into clinical routine. Our
findings emphasise that optimal stroke care does not end with hospi-
tal discharge but should extend to a comprehensive 3-month reas-
sessment performed by a multidisciplinary stroke team.on. For this analysis, the pre-specified threshold for statistical significance was P  0.05.
ore than one endpoint. Relative risk refers to hazard ratios or risk ratios (dependent on
y data from the trial centre in Innsbruck. ALT denotes alanine aminotransferase, CI con-
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